Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

- PMLiVE

Galderma launches Rosacea awareness campaign

Campaign comes on the back of Rosacea Awareness Month

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Voice biomarker device could diagnose depression, heart disease

Sonde Health raises $16m in series A round

- PMLiVE

Gyroscope advances gene therapy platform, merges with Orbit

News mirrors Ocugen and Histogenics merger

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

- PMLiVE

PMEA names Dr Paul Stuart-Kregor as Chair of Judges

He succeeds Professor Brian Smith

The Orkambi row explained

Q&A and timeline

The playbook of a ‘reluctant creative’

Are we all capable of being creative?

Bedrock Healthcare Communications

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links